Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05751928 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Name: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma — clinical trial record (NCT05751928)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NEO-MIMAJOR

StatusActive, Not Recruiting

PhasePhase 3

SponsorBiocad

Started2023-04-05

View on ClinicalTrials.gov ↗

Amendment history

2025-07-07

Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v3

Trial statusRecruiting→Active, Not Recruiting

Enrollment targetestimated 410→confirmed 411

Study sitesdetails revised at 36 of 36 sites

2024-11-22

Study Status v2

Start dateestimated 2023-03→confirmed 2023-04-05

2023-03-13

Study Status, Conditions v1

Re-verified, no change to tracked fields

2023-02-21

Original filing

Biocad

26 trials monitored

See all monitored trials

Melanoma

1,020 trials monitored

See 45 trials at risk

This study is an open-label, randomized, comparative phase III study, which will include subjects with resectable stage III skin melanoma (up to 3 resectable transient metastases are acceptable).

Trial Details

NCT Number	NCT05751928
Lead Sponsor	Biocad
Conditions	Melanoma Stage III, Melanoma (Skin)
Enrollment	411 participants
Start Date	2023-04-05
Primary Completion	2027-01 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2025-07-08